Publications by authors named "D Niemann"
Purpose: The critical time between stroke onset and treatment was targeted for reduction by integrating physiological imaging into the angiography suite, potentially improving clinical outcomes. The evaluation was conducted to compare C-Arm cone beam CT perfusion (CBCTP) with multi-detector CT perfusion (MDCTP) in patients with acute ischemic stroke (AIS).
Approach: Thirty-nine patients with anterior circulation AIS underwent both MDCTP and CBCTP.
Article Synopsis
- The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
- Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
- The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
Periodontal disease poses significant challenges to the long-term stability of oral health by destroying the supporting structures of teeth. Guided tissue regeneration techniques, particularly barrier membranes, enable local regeneration by providing an isolated, protected compartment for osseous wound healing while excluding epithelial tissue. Here, this study reports on a thermosensitive periodontal membrane (TSPM) technology designed to overcome the mechanical limitations of current membranes through a semi-interpenetrating network of high molecular weight poly(L-lactic acid) (PLLA) and in situ-polymerized mesh of poly(ε-caprolactone)diacrylate (PCL-DA), and poly lactide-co-glycolide diacrylate (PLGA-DA).
View Article and Find Full Text PDFPurpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.
Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.
Article Synopsis
- In newly diagnosed acute myeloid leukemia (AML), immediate treatment is typical; however, sometimes treatment may be delayed to evaluate other health issues or risks.
- A study analyzed the effects of the timing of treatment initiation on outcomes for patients receiving venetoclax-based therapy, comparing two patient groups with average ages of 76 and 72.
- Results showed no significant difference in overall survival or complications (like severe infections) between those who started treatment within 10 days versus later, suggesting that delaying therapy may be safe for certain patients with proper monitoring.